Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 118

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 118
---
 to consummate a business combination from July 11, 2024 to August 11, 2024. An additional $100,000 was drawn during the three months ended March 31, 2025. As of March 31, 2025, $115,037 remained outstanding under the Sponsor Extension Convertible Promissory Note issued to Sponsor. |

53

| (5) | On August 9, 2024, Denali issued a convertible promissory note in the total principal amount of up to $180,000 to Scilex (the “Scilex Convertible Promissory Note”). The Scilex Convertible Promissory Note was issued with an initial principal balance of $15,037, with the remaining $164,963 drawable at Denali’s request and upon the consent of Scilex prior to the maturity of the Scilex Convertible Promissory Note. As of March 31, 2025, Scilex has deposited an aggregate of $120,483, drawn down from the Scilex Convertible Promissory Note, to the Trust Account to extend the time Denali has to consummate an initial business combination to June 11, 2025. On January 6, 2025, February 11, 2025 and March 11, 2025, Scilex deposited an aggregate of $45,191, drawn down from the Scilex Convertible Promissory Note, to the Trust Account to extend the time the Company has to consummate an initial business combination to April 11, 2025. Subsequent to the quarter ended March 31, 2025, Scilex deposited an aggregate of $1,750 on April 11, 2025 and May 9, 2025, drawn down from the Scilex Convertible Promissory Note, to the Trust Account to extend the time the Company has to consummate an initial business combination to June 11, 2025. On June 11, 2025, Scilex deposited an additional $874.78, drawn down from the Scilex Convertible Promissory Note, to the Trust Account to extend the time the Company has to consummate an initial business combination to July 11, 2025. |

The reimbursements payable to, or the conversion of shares by the Sponsor, FutureTech and Scilex at Closing will not result in a material dilution of the equity interests of